Company intelligence / Profile preview

Panacela Labs

New York, United Statesprweb.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

Panacela Labs has completed a Phase I clinical trial with its lead candidate Mobilan, an immunotherapy targeting TLR5 for non-metastatic prostate cancer. The study demonstrated safety, pharmacokinetics, and pharmacodynamics. Another key asset, Xenomycins—a novel antimicrobial—has shown promising preclinical efficacy against fungal pathogens such as Candida and Aspergillus.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculesImmunotherapeuticsPossibly others in preclinical development
Industry: Biotech

Drug pipeline

3 assets

mobilan

2 more assets in the full pipeline.

Request access →

Partnerships

Roswell Park Cancer InstituteChildren’s Cancer Institute AustraliaCleveland Clinic FoundationRUSNANO investment partnership

Beyond the preview

Go deeper on Panacela Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panacela Labs.

Explore the full profile